262 related articles for article (PubMed ID: 33619778)
21. Pooled safety analysis of calcipotriol plus betamethasone dipropionate gel for the treatment of psoriasis on the body and scalp.
Kragballe K; van de Kerkhof P
J Eur Acad Dermatol Venereol; 2014 May; 28 Suppl 2():10-21. PubMed ID: 24684739
[TBL] [Abstract][Full Text] [Related]
22. Effectiveness comparison and incremental cost-per-responder analysis of calcipotriene 0.005%/betamethasone dipropionate 0.064% foam vs. halobetasol 0.01%/tazarotene 0.045% lotion for plaque psoriasis: a matching-adjusted indirect comparative analysis.
Wu JJ; Hansen JB; Patel DS; Nyholm N; Veverka KA; Swensen AR
J Med Econ; 2020 Jun; 23(6):641-649. PubMed ID: 31985301
[No Abstract] [Full Text] [Related]
23. Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam Compared with Betamethasone 17-Valerate-Medicated Plaster for the Treatment of Psoriasis.
Queille-Roussel C; Rosen M; Clonier F; Nørremark K; Lacour JP
Clin Drug Investig; 2017 Apr; 37(4):355-361. PubMed ID: 27995521
[TBL] [Abstract][Full Text] [Related]
24. Quality of life and patient-perceived symptoms in patients with psoriasis undergoing proactive or reactive management with the fixed-dose combination Cal/BD foam: A post-hoc analysis of PSO-LONG.
Jalili A; Calzavara-Pinton P; Kircik L; Lons-Danic D; Pink A; Tyring S; de la Cueva P; Gooderham M; Segaert S; Nyholm N; Thoning H; Petersen B; Thaçi D
J Eur Acad Dermatol Venereol; 2022 Jan; 36(1):60-67. PubMed ID: 34543474
[TBL] [Abstract][Full Text] [Related]
25. Calcipotriol/betamethasone dipropionate aerosol foam for the treatment of psoriasis vulgaris: a review of real-world evidence (RWE).
Gerdes S; Velasco M; Wu JJ; Hubo M; Veverka KA
J Dermatolog Treat; 2021 Dec; 32(8):883-893. PubMed ID: 31986945
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of fixed-dose combination calcipotriol/betamethasone dipropionate foam for the treatment of psoriasis.
Stein Gold L; Paul C; Romiti R
J Eur Acad Dermatol Venereol; 2021 Feb; 35 Suppl 1():10-19. PubMed ID: 33619777
[TBL] [Abstract][Full Text] [Related]
27. Patient-Reported Satisfaction With the Fixed Combination Calcipotriene/Betamethasone Dipropionate Foam for Plaque Psoriasis.
Gorelick J; Cantrell W; Kucera K; Veverka KA; Gooding K
J Drugs Dermatol; 2018 Aug; 17(8):880-884. PubMed ID: 30124727
[TBL] [Abstract][Full Text] [Related]
28. Early efficacy and safety data with fixed-dose combination calcipotriol/betamethasone dipropionate foam attributed to mechanism of absorption and steroid potency.
Tada Y; Iversen L; Koo J
J Eur Acad Dermatol Venereol; 2021 Feb; 35 Suppl 1(Suppl 1):5-9. PubMed ID: 33619779
[TBL] [Abstract][Full Text] [Related]
29. Real-world experience of calcipotriene and betamethasone dipropionate foam 0.005%/0.064% in the treatment of adults with psoriasis in the United States.
Wu JJ; Veverka KA; Lu M; Armstrong AW
J Dermatolog Treat; 2019 Aug; 30(5):454-460. PubMed ID: 30307343
[No Abstract] [Full Text] [Related]
30. Cost per PASI-75 responder of calcipotriol plus betamethasone dipropionate cutaneous foam versus nonbiologic systemic therapies for the treatment of plaque psoriasis in seven European countries.
Balak DMW; Carrascosa JM; Gregoriou S; Calzavara-Pinton P; Bewley A; Antunes J; Nyeland ME; Viola MG; Sawyer LM; Becla L
J Dermatolog Treat; 2021 Nov; 32(7):701-708. PubMed ID: 31940225
[TBL] [Abstract][Full Text] [Related]
31. Calcipotriol/betamethasone dipropionate formulations for psoriasis: an overview of the options and efficacy data.
Megna M; Cinelli E; Camela E; Fabbrocini G
Expert Rev Clin Immunol; 2020 Jun; 16(6):599-620. PubMed ID: 32476507
[TBL] [Abstract][Full Text] [Related]
32. Treating Scalp Psoriasis with Calcipotriene/Betamethasone Dipropionate Fixed-dose Combination Cutaneous Foam: Review of Phase 2 Data.
Petersen B; Lebwohl M
J Drugs Dermatol; 2020 Aug; 19(8):784-786. PubMed ID: 32820879
[TBL] [Abstract][Full Text] [Related]
33. Vasoconstrictor potency of fixed-dose combination calcipotriol (50 μg/g) and betamethasone dipropionate (0.5 mg/g) cutaneous foam versus other topical corticosteroids used to treat psoriasis vulgaris.
Queille-Roussel C; Nielsen J; Lacour JP
J Dermatolog Treat; 2019 Sep; 30(6):529-533. PubMed ID: 30582717
[No Abstract] [Full Text] [Related]
34. Real-life effectiveness of once-daily calcipotriol and betamethasone dipropionate gel vs. ointment formulations in psoriasis vulgaris: final analysis of the 52-week PRO-long study.
Lambert J; Hol CW; Vink J
J Eur Acad Dermatol Venereol; 2015 Dec; 29(12):2349-55. PubMed ID: 26337069
[TBL] [Abstract][Full Text] [Related]
35. Calcipotriol/betamethasone aerosol foam (Enstilum) for the topical treatment of psoriasis vulgaris in routine practice in Korea: A prospective, noninterventional, multicenter study of treatment outcomes and patient satisfaction.
Jo SJ; Park CJ; Bang CH; Jeong KH; Shin BS; Kim DH; Park HJ; Kim BS; Song HJ; Lee JH; Youn SW
J Dermatol; 2022 Nov; 49(11):1085-1095. PubMed ID: 35848089
[TBL] [Abstract][Full Text] [Related]
36. Fixed-Combination Calcipotriene Plus Betamethasone Dipropionate Aerosol Foam Is Well Tolerated in Patients with Psoriasis Vulgaris: Pooled Data from Three Randomized Controlled Studies.
Menter A; Gold LS; Koo J; Villumsen J; Rosén M; Lebwohl M
Skinmed; 2017; 15(2):119-124. PubMed ID: 28528605
[TBL] [Abstract][Full Text] [Related]
37. Fixed Combination Calcipotriene and Betamethasone Dipropionate (Cal/BD) Foam for Beyond-Mild Psoriasis: A Possible Alternative to Systemic Medication.
Kircik L; Stein Gold L; Teng J; Moore A; Cantrell W; Alonso-Llamazares J; Koo J
J Drugs Dermatol; 2020 Aug; 19(8):723-732. PubMed ID: 32845591
[TBL] [Abstract][Full Text] [Related]
38. Sub-population analysis of patients with plaque psoriasis treated with calcipotriol/betamethasone aerosol foam; effectiveness and patient satisfaction, according to baseline disease severity and prior psoriasis treatment experience, in a Greek population.
Rigopoulos D; Lazaridou E; Papadavid E; Georgiou S; Chasapi V; Sfaelos K; Cheliotis G; Ioannides D
Dermatol Ther; 2022 Jun; 35(6):e15484. PubMed ID: 35373423
[TBL] [Abstract][Full Text] [Related]
39. Enhanced vasoconstrictor potency of the fixed combination calcipotriol plus betamethasone dipropionate in an innovative aerosol foam formulation vs. other corticosteroid psoriasis treatments.
Queille-Roussel C; Bang B; Clonier F; Lacour JP
J Eur Acad Dermatol Venereol; 2016 Nov; 30(11):1951-1956. PubMed ID: 27306589
[TBL] [Abstract][Full Text] [Related]
40. Prospective Observational Evaluation of Fixed Combination Calcipotriol/Betamethasone Aerosol Foam (Enstilar®) in the Management of Psoriasis with Scalp Involvement in Everyday Clinical Practice (the CAPITIS Study).
Staubach P; Wurzer E; Hutt HJ; von Kiedrowski R
Dermatology; 2023; 239(2):206-216. PubMed ID: 36716728
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
